COMMUNIQUÉS West-GlobeNewswire

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
07/01/2026
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On [...]
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
07/01/2026
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
07/01/2026
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and [...]
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
07/01/2026
Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE [...]
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
07/01/2026
BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month [...]
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
07/01/2026
- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast Europe, Israel, the [...]
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
07/01/2026
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME [...]
Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and [...]
JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
07/01/2026
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in upcoming clinical [...]
Kraig Biocraft Laboratories Takes Possession of Three Strategic Mulberry Fields Advancing Massive Spider Silk Production Ramp-Up
07/01/2026
ANN ARBOR, Mich., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or “Kraig’s”), a world leader in spider silk technology*, today announced that it has [...]
Glucose Health, Inc. Board Members Confirm Participation in Preferred Share Conversion at 85% Premium to Market and Introduce New Revenue Growth Strategy
07/01/2026
BENTONVILLE, Ark., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a consumer-health company specializing in soluble-fiber nutrition products for metabolic support, today confirmed that all members [...]
BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™
07/01/2026
New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients BURLINGTON, Mass. and JERUSALEM, Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay [...]
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
07/01/2026
Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA ® , povorcitinib, ILUMYA®, ODOMZO ® , REMICADE ® , and STELARA ® Dr [...]
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
07/01/2026
FDA assigned PDUFA target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN. Atacicept received FDA Breakthrough Therapy Designation for the [...]
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
07/01/2026
Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare disease Kyntra Bio will begin trading on Nasdaq under the trading [...]
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
Presentation scheduled for Tuesday, January 13, 2026, at 1:30 PM PST NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and [...]
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
CLEVELAND, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and [...]
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]

Pages